We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tenet Healthcare (THC) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
In the latest trading session, Tenet Healthcare (THC - Free Report) closed at $55.62, marking a +0.07% move from the previous day. This change lagged the S&P 500's 1.04% gain on the day. At the same time, the Dow added 0.58%, and the tech-heavy Nasdaq gained 2.52%.
Heading into today, shares of the hospital operator had gained 11.94% over the past month, outpacing the Medical sector's loss of 5.72% and the S&P 500's loss of 0.15% in that time.
THC will be looking to display strength as it nears its next earnings release. On that day, THC is projected to report earnings of $0.72 per share, which would represent a year-over-year decline of 43.75%. Our most recent consensus estimate is calling for quarterly revenue of $4.75 billion, up 5.14% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $4.48 per share and revenue of $19.38 billion. These totals would mark changes of -5.29% and +9.84%, respectively, from last year.
Any recent changes to analyst estimates for THC should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 52.03% higher. THC is holding a Zacks Rank of #2 (Buy) right now.
Digging into valuation, THC currently has a Forward P/E ratio of 12.41. This represents a discount compared to its industry's average Forward P/E of 18.29.
The Medical - Hospital industry is part of the Medical sector. This group has a Zacks Industry Rank of 89, putting it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow THC in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Tenet Healthcare (THC) Gains But Lags Market: What You Should Know
In the latest trading session, Tenet Healthcare (THC - Free Report) closed at $55.62, marking a +0.07% move from the previous day. This change lagged the S&P 500's 1.04% gain on the day. At the same time, the Dow added 0.58%, and the tech-heavy Nasdaq gained 2.52%.
Heading into today, shares of the hospital operator had gained 11.94% over the past month, outpacing the Medical sector's loss of 5.72% and the S&P 500's loss of 0.15% in that time.
THC will be looking to display strength as it nears its next earnings release. On that day, THC is projected to report earnings of $0.72 per share, which would represent a year-over-year decline of 43.75%. Our most recent consensus estimate is calling for quarterly revenue of $4.75 billion, up 5.14% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $4.48 per share and revenue of $19.38 billion. These totals would mark changes of -5.29% and +9.84%, respectively, from last year.
Any recent changes to analyst estimates for THC should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 52.03% higher. THC is holding a Zacks Rank of #2 (Buy) right now.
Digging into valuation, THC currently has a Forward P/E ratio of 12.41. This represents a discount compared to its industry's average Forward P/E of 18.29.
The Medical - Hospital industry is part of the Medical sector. This group has a Zacks Industry Rank of 89, putting it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow THC in the coming trading sessions, be sure to utilize Zacks.com.